natgillin/translations-raw huggingface dataset:
Common side effects (may affect up to 1 in 10 people): nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).
siljenje na bruhanje/bruhanje nenormalno uriniranje utrujenost omotica (tudi pri vstajanju iz ležečega ali sedečega položaja)krvne preiskave lahko pokažejo zvišanje vrednosti encima, ki kaže na delovanje mišic in srca (encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
Irbesartan/Hydrochlorothiazide Teva is a combination of two active substances, irbesartan and hydrochlorothiazide.
Irbesartan/hidroklorotiazid Teva je kombinacija dveh učinkovin, irbesartana in hidroklorotiazida.
The active ingredients are irbesartan and hydrochlorothiazide.
Učinkovini sta irbesartan in hidroklorotiazid.
A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.
Že pred načrtovano nosečnostjo je treba izbrati drugo primerno zdravilo.
For Irbesartan/Hydrochlorothiazide Teva packaged in aluminium - aluminium blisters: This medicinal product does not require any special storage conditions.
Za zdravilo Irbesartan/hidroklorotiazid Teva v aluminij - aluminijevih pretisnih omotih: : Za shranjevanje zdravila niso potrebna posebnia navodila.
For Irbesartan/Hydrochlorothiazide Teva packaged in white opaque PVC-PVdC - aluminium blisters: Do not store above 30°C.
Za zdravilo Irbesartan/hidroklorotiazid Teva v belih neprozornih PVC-PVdC - aluminijevih pretisnih omotih: Shranjujte pri temperaturi do 30°C.
Irbesartan/Hydrochlorothiazide Teva is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Irbesartan/hidroklorotiazid Teva ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis.
hipokloremija, hiponatriemija) in dehidracija, ki sta posledica čezmerne diureze.
Latent diabetes mellitus may become manifest during thiazide therapy.
Med zdravljenjem s tiazidnimi diuretiki se lahko latentni diabetes mellitus spremeni v manifestnega.
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe:
Thiazide therapy may impair glucose tolerance.
Tiazidni diuretiki lahko zmanjšajo toleranco za glukozo.
White opaque PVC-PVdC - Aluminium blisters: Do not store above 30°C.
Beli neprozorni PVC-PVdC - aluminijevi pretisni omoti: Shranjujte pri temperaturi do 30°C.
You should also tell your doctor:
Posvetujte se tudi,
Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Bolniki morajo uživati primerno količino tekočine in po uvedbi sočasne uporabe je priporočljivo redno spremljanje delovanja ledvic.
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• sočasna uporaba zdravila Irbesartan/hidroklorotiazid Teva in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (hitrost glomerularne filtracije < 60 ml/min/1,73 m2) (glejte poglavji 4.5 in 5.1).
Irbesartan/Hydrochlorothiazide Teva is not recommended for use in children and adolescents because the safety and efficacy have not been established.
Varnost in učinkovitost zdravila Irbesartan/hidroklorotiazid Teva nista bili dokazani, zato uporaba pri otrocih in mladostnikih ni priporočljiva.
Uncommon side effects (may affect up to 1 in 100 people): diarrhoea low blood pressure fainting heart rate increased flushing swelling sexual dysfunction (problems with sexual performance) blood tests may show lowered levels of potassium and sodium in your blood.
driska nizek krvni tlak omedlevica hiter srčni utrip zardevanje otekline spolne motnje (težave pri spolnih odnosih)krvne preiskave lahko pokažejo znižane vrednosti kalija in natrija v krvi.
The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).
Uporaba antagonistov angiotenzina II v prvem trimesečju nosečnosti ni priporočljiva (glejte poglavje 4.4).
If any of these side effects causes you problems, talk to your doctor.
Če imate težave zaradi katerega od navedenih neželenih učinkov, se posvetujte z zdravnikom.
Less than 2 % of the dose is excreted in the urine as unchanged irbesartan.
V nespremenjeni obliki se s sečem izloči manj kot 2 % odmerka.
The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy.
Pri bolnikih, ki so se zdravili s kombinacijo, so poročali o enaki vrsti in pogostnosti neželenih učinkov kot pri bolnikih, ki so se zdravili samo z eno zdravilno učinkovino.
There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide combination.
Dokazov o mutagenem in klastogenem delovanju kombinacije irbesartan/hidroklorotiazid ni.
Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
V primeru izpostavljenosti antagonistom angiotenzina II od drugega trimesečja nosečnosti dalje se priporoča ultrazvočni pregled lobanje in delovanja ledvic.
Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice seen as yellowing of the skin and/or whites of the eyes; inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
Neželeni učinki, ki so povezani z jemanjem hidroklorotiazida samega: Izguba apetita, draženje želodca, krči v želodcu, zaprtost, zlatenica (rumeno obarvanje kože in/ali očesnih beločnic), vnetje trebušne slinavke, za katerega je značilna huda bolečina v zgornjem predelu trebuha, ki jo pogosto spremlja slabost in bruhanja, motnje spanja, depresija, zameglejn vid, zmanjšanje števila belih krvnih celic, ki ima za posledico lahko pogostejše okužbe in zvišano telesno temperaturo, zmanšanje števila trombocitov (krvnih celic, pomembnih za strjevanje krvi), zmanjšanje števila krvnih celic (anemija) za katero je značilna utrujenost, glavobol, zasoplost pri tlesni aktivnosti, omotica in bledica, bolezen ledvic, bolezen pljuč, vključno s pljučnico in kopičenjem tekočine v pljučih, večja občutljivost kože za sončno svetlobo, vnetje krvnih žil, kožna bolezen za katero je značilno luščenje kože po celem telesu, kožni eritematozni lupus, ki se kaže z izpuščajem po obrazu, vratu in lasisšču, alergijske reakcije, oslabelost in krči mišic, spremembe srčnega utripa, znižanje krvnega tlaka po spremembi položaja telesa, otekanje žlez slinavk, zvišanje vrednosti sladkorja v krvi, sladkor v urinu, zvišanje vrednosti nekaterih maščob v krvi, zvišanje vrednosti sečne kisline v krvi, kar lahko povzroči protin.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Obstajajo dokazi, da sočasna uporaba zaviralcev ACE, blokatorjev receptorjev angiotenzina II ali aliskirena poveča tveganje za hipotenzijo, hiperkaliemijo in zmanjšano delovanje ledvic (vključno z akutno odpovedjo ledvic).
Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with irbesartan and hydrochlorothiazide combinations.
Tiazidi zmanjšujejo ledvični očistek litija, zato se med zdravljenjem s kombinacijo irbesartana in hidroklorotiazida poveča nevarnost zastrupitve z litijem.
if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan/Hydrochlorothiazide Teva.
srbenje, otekline, pojav mehurjev) pojavijo hitreje kot normalno če imate predvideno operacijo (kirurški poseg) ali boste prejeli anestetik če se med jemanjem zdravila Irbesartan/hidroklorotiazid Teva pojavijo spremembe vida ali bolečina v enem ali obeh očesih.
Side effects reported in clinical studies for patients treated with the combination of irbesartan and hydrochlorothiazide were:
Med kliničnimi študijami so pri bolnikih, ki so se zdravili s kombinacijo irbesartana in hidroklorotiazida, poročali o naslednjih neželenih učinkih:
Irbesartan/Hydrochlorothiazide Teva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Mehanizem delovanja Zdravilo Irbesartan/hidroklorotiazid Teva je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Hydrochlorothiazide is a thiazide diuretic.
Hidroklorotiazid je tiazidni diuretik.
6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
• pri nekaj podganah, ki so v študiji toksičnosti 6 mesecev dobivale po 90 mg irbesartana na kg/dan in 90 mg hidroklorotiazida na kg/dan ter kombinacijo irbesartana in hidroklorotiazida
The hydrochlorothiazide contained in this medicine could produce a positive result in an anti-doping test.
Zaradi hidroklorotiazida, ki ga zdravilo vsebuje, je lahko test za ugotavljanje jemanja nedovoljenih substanc (antidopinški test) pozitiven.
The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not been evaluated in animal studies.
Kancerogenega delovanja te kombinacije v študijah na živalih niso ugotavljali.
Abnormal urination Impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4)
vključno s posameznimi primeri odpovedi ledvic pri bolnikih s tveganjem (glejte poglavje 4.4)
Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Antiholinergična zdravila (npr. atropin, beperiden) lahko zmanjšajo motaliteto prebavil in praznjenje želodca, zato se zveča biološka uporabnost tiazidnih diuretikov.
Special Populations
Posebne skupine bolnikov
No dosage adjustment is necessary in older people.
Starejšim bolnikom odmerka ni treba prilagoditi.
Irbesartan is not removed by haemodialysis.
Irbesartan se s hemodializo ne odstrani iz organizma.
In this regard, a limit of quantification of 0.03 ppm for NDMA and NDEA would be achievable according to the available data on analytical methods.
V tem pogledu bi bila v skladu z razpoložljivimi podatki o analitskih metodah dosegljiva meja določljivosti za NDMA in NDEA 0,03 ppm.
Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and 1-2.5 hours for hydrochlorothiazide.
Najvišja plazemska koncentracija irbesartana se doseže 1,5-2 ure po peroralnem jemanju, najvišja plazemska koncentracija hidroklorotiazida pa čez 1-2,5 ure.
Talk to your doctor before taking Irbesartan/Hydrochlorothiazide Teva and if any of the following apply to you:
Pred začetkom jemanja zdravila Irbesartan/hidroklorotiazid Teva se posvetujte z zdravnikom, če se karkoli od naslednjega nanaša na vas:
Concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatraemia.
Karbamazepin Sočasna uporaba karbamazepina in hidroklorotiazida je povezana s tveganjem za pojav simptomatske hiponatriemije, zato je v tem primeru treba spremljati vrednosti elektrolitov.
Preparations containing lithium should not be taken with Irbesartan/Hydrochlorothiaizde Teva without close supervision by your doctor.
Zdravila, ki vsebujejo litij, smete z zdravilom Irbesartan/hidroklorotiazid Teva jemati le pod strogim zdravniškim nadzorom.
This could be a sign that you are developing glaucoma, increased pressure in your eye(s).
To je lahko znak pojava glavkoma, zvišanja tlaka v enem ali obeh očesih.
Tables 2 and 3 below detail the adverse reactions reported with the individual components of Irbesartan/Hydrochlorothiazide Teva.
V tabeli 2 in 3 so navedeni neželeni učinki, o katerih so poročali pri uporabi posamezne zdravilne učinkovine zdravila Irbesartan/hidroklorotiazid Teva.
if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Irbesartan/Hydrochlorothiazide Teva).
Svojemu zdravniku morate povedati: če imate dieto z zmanjšanim vnosom soli če imate znake, kot so nenormalna žeja, suha usta, splošna oslabelost, zaspanost, bolečine ali krči v mišicah, siljenje na bruhanje ali nenormalno hiter srčni utrip, ki so lahko posledica prevelikega učinka hidroklorotiazida (ki ga vsebuje zdravilo Irbesartan/hidroklorotiazid Teva) če vaša koža postane bolj občutljiva na sonce oziroma se znaki sončnih opeklin (kot so pordelost,
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed.
Nemelanomski kožni rak: Na podlagi obstoječih podatkov epidemioloških študij so ugotovili, da obstaja razmerje med kumulativnim odmerkom hidroklorotiazida in nemelanomskim kožnim rakom.
The pharmacokinetic of digoxin was not altered by co-administration of irbesartan.
Farmakokinetika digoksina se ob sočasnem dajanju irbesartana ni spremenila.
There is no difference in response to irbesartan/hydrochlorothiazide, regardless of age or gender.
Odziv na zdravljenje s kombinacijo irbesartana in hidroklorotiazida ni odvisen od starosti ali spola.
The other side of the tablet debossed with the number "7239".
Na drugi strani tablete je vtisnjena številka "7239".
You can take Irbesartan/Hydrochlorothiazide Teva with or without food.
Zdravilo Irbesartan/hidroklorotiazid Teva lahko jemljete s hrano ali brez nje.
Due to the hydrochlorothiazide component, Irbesartan/Hydrochlorothiazide Teva is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min).
Zdravilo Irbesartan/hidroklorotiazid Teva vsebuje hidroklorotiazid, zato za bolnike s hudo motenim delovanjem ledvic (očistek kreatinina < 30 ml/min) ni primeren.
There is no experience regarding the administration of Irbesartan/Hydrochlorothiazide Teva in patients with a recent kidney transplantation.
Izkušenj z uporabo zdravila Irbesartan/hidroklorotiazid Teva pri bolnikih po nedavni presaditvi ledvice ni.
Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg combination may respond when uptitrated to 300 mg/25 mg.
Omejeni klinični podatki (7 od 22 bolnikov) kažejo, da se lahko bolniki, ki niso urejeni s kombinacijo
Anaphylactic reaction including anaphylactic shock
Bolezni imunskega sistema neznana anafilaktična reakcija vključno z anafilaktičnim šokom
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free'.
Pomožna snov To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na filmsko obloženo tableto, kar v bistvu pomeni
In addition to the side effects listed above, chest pain, severe allergic reactions (anaphylactic shock) and decrease in the number of platelets (a blood cell essential for the clotting of the blood) have also been reported.
Neželeni učinki, ki so povezani z jemanjem irbesartana samega Poleg zgoraj naštetih neželenih učinkov so poročali tudi o pojavu bolečine v prsnem košu, hudih alergijskih reakcijah (anafilaktični šok) in zmanjšanju števila trombocitov (krvne celice, ki so nujne za strjevanje krvi).
Acute Myopia and Secondary Acute Angle-Closure Glaucoma Sulfonamide drugs or sulfonamide derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure glaucoma.
Zdravila, ki vsebujejo sulfonamide ali njihove derivate lahko povzročijo idiosinkratično reakcijo s posledično prehodno kratkovidnostjo in akutnim glavkomom z zaprtim zakotjem.
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Zdravilo Irbesartan/hidroklorotiazid Teva je na voljo v pakiranjih po 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 in 100 filmsko obloženih tablet v neperforiranih pretisnih omotih; perforirani pretisni omot z enkratnimi odmerki po 50x1 filmsko obložena tableta in koledarsko pakiranje v neperforiranem pretisnem omotu po 28 filmsko obloženih tablet.
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebosubtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
Ocenjevanje krvnega tlaka pri bolnikih, ki so jim ga merili 24 ur in so dobivali enkrat na dan po 150 mg irbesartana in 12,5 mg hidroklorotiazida je pokazal, da se je krvni tlak v obdobju 24 ur konstantno zmanjševal in da je srednje 24 urno znižanje sistoličnega krvnega tlaka 15,8 mmHg večje kot pri uporabi placeba, diastoličnega pa za 10,0 mmHg.
Irbesartan/Hydrochlorothiazide Teva is not indicated in patients with severe hepatic impairment.
Zdravilo Irbesartan/hidroklorotiazid Teva ni primerno za bolnike s hudo jetrno okvaro.
Therefore, the combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.4).
Sočasna uporaba litija in zdravila Irbesartan/hidroklorotiazid Teva zato ni priporočljiva (glejte poglavje 4.4).
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg
Irbesartan/hidroklorotiazid Teva 300 mg/25 mg
These findings were also observed with lower doses of this other angiotensin-II antagonist when given in combination with hydrochlorothiazide.
To so ugotovili tudi med kombinirano uporabo hidroklorotiazida in majhnega odmerka tega drugega antagonista angiotenzina II.
Contents of the pack and other information What Irbesartan/Hydrochlorothiazide Teva contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Irbesartan/hidroklorotiazid Teva
No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity.
Podganje samice so dobivale toksične odmerke irbesartana in hidroklorotiazida v kombinaciji, vendar se teratogeni učinki niso pojavili.
Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).
Predhoden pojav alergije na sulfonamide ali peniciline je lahko dejavnik tveganja za razvoj akutnega glavkoma z zaprtim zakotjem (glejte poglavje 4.8).
Angiotensin II Receptor Antagonists (AIIRAs)
Antagonisti angiotenzina II
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for this is unknown.
Po zaužitju odmerka, večjega od 600 mg, ne pride do proporcionalnega zvečanja absorpcije; mehanizem tega pojava ni znan.
Irbesartan/Hydrochlorothiazide Teva with alcohol
Zdravilo Irbesartan/hidroklorotiazid Teva skupaj z alkoholom
In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required.
Diabetikom je treba po potrebi prilagoditi odmerek insulina ali peroralnih antidiabetikov.
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Med hkratnim zdravljenjem z irbesartanom se verjetno, zaradi blokade sistema renin-angiotenzin-aldosteron, zmanjša izplavljanje kalija, ki ga povzročajo ti diuretiki.
There is no clinical experience with Irbesartan/Hydrochlorothiazide Teva in patients with hepatic impairment.
Kliničnih izkušenj z uporabo zdravila Irbesartan/hidroklorotiazid Teva pri bolnikih z jetrno okvaro ni.
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Irbesartan/Hydrochlorothiazide Teva (see section 4.5).
Pri hkratnem zdravljenju z diuretiki, ki varčujejo kalij, pripravki s kalijem, nadomestki soli, ki vsebujejo kalij, in zdravilom Irbesartan/hidroklorotiazid Teva je potrebna posebna previdnost (glejte poglavje 4.5).
Tablet core: povidone, pregelatinized starch (maize), poloxamer 188, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate.
Jedro tablete: povidon, predgelirani škrob (koruzni), poloksamer 188, mikrokristalna celuloza,
There were no toxicological findings observed of relevance to human therapeutic use.
Toksičnega delovanja, ki bi bilo pomembno tudi za terapevtske odmerke pri ljudeh, niso dokazali.
Pack size of 28 film-coated tablets in non-perforated calendar blisters.
Koledarsko pakiranje v neperforiranem pretisnem omotu po 28 filmsko obloženih tablet.
After either oral or intravenous administration of 14C irbesartan, about 20 % of the radioactivity is recovered in the urine, and the remainder in the faeces.
C se s sečem izloči približno 20 % radioaktivne snovi, preostanek pa z blatom.
Thiazides should be used with caution in patients with impaired hepatic function.
Pri bolnikih z okvarjeno jetrno funkcijo je treba tiazidne diuretike uporabljati zelo previdno.
No specific information is available on the treatment of overdose with irbesartan and hydrochlorothiazide combinations.
O zdravljenju posledic prevelikega odmerjanja kombinacije irbesartana in hidroklorotiazida ni specifičnih podatkov.
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan/Hydrochlorothiazide Teva” and “Warnings and precautions”).
Če jemljete zaviralec ACE ali aliskiren (glejte tudi informacije pod naslovoma " Ne jemljite zdravila